Goldman Sachs’s BridgeBio Oncology BBOT Stock Holding History
Bought
Maintained
Sold
Other funds holding BBOT
Goldman Sachs's BBOT Position: Q3 2026 in Review
Goldman Sachs increased its BridgeBio Oncology (BBOT) stake by 135% in Q3 2026, buying an estimated $1.07M and bringing the position to 239,614 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #5255.
Goldman Sachs first reported a position in BBOT in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.5M in Q1 2026. 89 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.
- Goldman Sachs held 239,614 shares of BridgeBio Oncology worth $982K as of Q3 2026.
- Goldman Sachs bought 137,529 BridgeBio Oncology shares in Q3 2026, an estimated $1.07M.
- BridgeBio Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5255 holding.
- Goldman Sachs first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 4 quarters since.
- Goldman Sachs's BridgeBio Oncology position peaked at $1.5M in Q1 2026.
- 89 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.